Google Cloud Target & Lead Identification and Multiomics are set to improve drug discovery and precision medicine.
Google Cloud has it Launched Two AI-powered solutions to accelerate drug discovery and precision medicine development for related companies. On Tuesday, the tech giant’s cloud computing group said its newly launched AI-powered tools will greatly help biotech and pharmaceutical companies.
One of the tools, the Target and Lead Identification Suite, can help companies predict and understand protein structure. Meanwhile, another Google AI solution, Multiomics Suite, can help researchers collect, analyze and share large amounts of genomic data.
The recently launched Google Cloud AI drug discovery tools represent the company’s latest effort in the AI race. As AI technology continues to emerge, tech companies are struggling to gain the upper hand in a potentially very lucrative market. Google has come under increasing pressure to flex its AI muscles since Microsoft’s ChatGPT burst onto the scene late last year.
New AI-powered Google Cloud clusters are set to aid drug discovery processes by saving time and money
The two new Google Cloud clusters address a long-standing problem in the biopharmaceutical industry. As it is, bringing a new drug to the US market can be very time consuming and expensive. According to a recent Deloitte report, pharmaceutical companies can invest up to $2 billion to launch a single drug. However, these efforts only sometimes lead to successful results. For example, another Deloitte report said that drugs undergoing clinical trials face a 16% chance of approval in the United States. Moreover, this dismal success rate usually materializes alongside an intense and tedious research process that typically exceeds 10 years.
Shweta Manyar, Director of Global Life Sciences Solutions and Strategy at Google Cloud, spoke about the improvement tendencies of the two Google groups:
“We’re helping organizations get medicines to the right people faster. I’m personally very excited. This is something the team and I have been working on for a few years.”
Manyar added in a media session that the new offerings will save companies time and resources throughout the drug development process. Although both suites are immediately available to customers, Google said the associated costs vary by company. Despite this, several companies, including Pfizer (NYSE:PFE), Cerevel Therapeutics (NASDAQ:CERE), and Colossal Biosciences have begun using the products.
Google image identification solution
Google recently launched new tools to identify and classify fake and misleading images generated by artificial intelligence. The new features aim to stop the spread of misinformation by distinguishing between AI images and those captured by traditional means.
In an announcement leading up to the launch of the image recognition feature, Google said:
We will ensure that each of our AI-generated images has markup in the original file to give you context if you come across it outside of our platforms. Creators and publishers can add similar markup, so you can see a label in images in a Google search, marking it as from AI creation.
pixel fold
At its annual developer conference last week, Google unveiled its Pixel Fold smartphone. The tech giant has been teasing the device for weeks in the backlog and said it could start shipping next month.
The Pixel Fold starts at $1,799 and is likely to rival Samsung’s high-end phones.
the next
Tolu is a cryptocurrency and blockchain enthusiast based in Lagos. He likes to demystify cryptocurrency stories down to the bare essentials so that anyone anywhere can understand without much background knowledge. When not deep into cryptocurrency stories, Tolo enjoys music, loves to sing, and is a movie lover.
